BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase Ⅰ |
The First Affiliated Hospital of Nanchang University |
Multiple myeloma (MM) |
Details
|
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) |
|
Phase Not Specified |
Hebei Senlang BIOTECHNOLOGY Co., LTD |
Multiple myeloma (MM) |
Details
|
TNB-383B |
TNB-383B |
Phase Ⅰ |
Teneobio, Abbvie |
Multiple myeloma (MM) |
Details
|
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) |
|
Phase Ⅰ |
Yake Biotechnology |
Multiple myeloma (MM) |
Details
|
LCAR-B38M cell product |
JNJ-4528; JNJ-68284528; LCAR-B38M, JNJ 4528 |
Phase Ⅲ |
Nanjing Chuanqi Biotech, Janssen |
Multiple myeloma (MM) |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase Ⅰ |
Wuhan Union Hospital, Shengyan Pharmaceutical Technology |
Multiple myeloma (MM) |
Details
|
BCMA-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) |
|
IND Filing |
Unicar-Therapy Bio-medicine Technology |
Multiple myeloma (MM) |
Details
|
Idecabtagene vicleucel |
bb-2121 |
BLA Filing |
bluebird bio, Celgene |
Multiple myeloma (MM) |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase Ⅱ |
General Hospital of the People's Liberation Army |
Multiple myeloma (MM) |
Details
|
GC-012F |
GC-012F |
Phase Ⅰ |
Gracell Biotechnology |
Multiple myeloma (MM) |
Details
|
CC-98633 |
CC-98633 |
Phase Ⅰ |
Celgene |
Multiple myeloma (MM) |
Details
|
CART-BCMA |
CART-BCMA; MTV-273,CART BCMA,MTV273 |
Phase Ⅰ |
University of Pennsylvania, Novartis |
Multiple myeloma (MM) |
Details
|
P-BCMA-101 |
P-BCMA-101 |
Phase Ⅱ |
Poseida Therapeutics |
Multiple myeloma (MM) |
Details
|
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) |
|
Phase Ⅱ |
Asclepius Technology Company Group |
Multiple myeloma (MM) |
Details
|
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase Ⅰ |
iCell Gene Therapeutics |
Multiple myeloma (MM) |
Details
|
Anti-BCMA CAR T-cell therapy (Arcellx) |
CART-ddBCMA |
Phase Ⅰ |
Arcellx |
Multiple myeloma (MM) |
Details
|
HPN-217 |
HPN-217 |
Phase Ⅱ |
Harpoon Therapeutics, Abbvie |
Multiple myeloma (MM) |
Details
|
CC-99712 |
CC-99712 |
Phase Ⅰ |
Celgene |
Multiple myeloma (MM) |
Details
|
Human BCMA chimeric antigen receptor autologous T cell(Nanjing Reindeer Medical Technology) |
CT103A |
Phase Ⅰ |
Innovent Biologics, Nanjing IASO Biotherapeutics |
Multiple myeloma (MM) |
Details
|
MEDI-2228 |
MEDI-2228,MEDI 2228,MEDI2228 |
Phase Ⅰ |
MedImmune |
Multiple myeloma (MM) |
Details
|
SEA-BCMA |
SEA-BCMA; SGN-BCMA |
Phase Ⅰ |
Seattle Genetics |
Multiple myeloma (MM) |
Details
|
PBCAR-269A |
PBCAR-269A |
Phase Ⅱ |
Precision BioSciences |
Multiple myeloma (MM) |
Details
|
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase Ⅰ |
PersonGen Biomedicine, Second Affiliated Hospital of Suzhou UniversitySecond Affiliated Hospital of Suzhou University |
Multiple myeloma (MM) |
Details
|
BCMA CAR-T Cells (Pregene) |
|
Phase Ⅰ |
Pregene |
Multiple myeloma (MM) |
Details
|
bb-21217 |
bb-21217,bb 21217,bb21217 |
Phase Ⅰ |
bluebird bio, Celgene |
Multiple myeloma (MM) |
Details
|
AMG-420 |
AMG-420; BI-836909 |
Phase Ⅰ |
Micromet, Boehringer Ingelheim, Amgen |
Multiple myeloma (MM) |
Details
|
CTX-120 |
CTX-120 |
Phase Ⅰ |
CRISPR Therapeutics |
Multiple myeloma (MM) |
Details
|
KITE-585 |
KITE-585,KITE585 |
Phase Ⅰ |
Kite Pharma, National Cancer Institute |
Multiple myeloma (MM) |
Details
|
REGN-5459 |
REGN-5459 |
Phase Ⅱ |
Regeneron Pharmaceutical |
Multiple myeloma (MM) |
Details
|
PF-06863135 |
PF-06863135,PF 06863135 |
Phase Ⅰ |
Pfizer |
Multiple myeloma (MM) |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase Ⅰ |
iCell Gene Therapeutics |
Multiple myeloma (MM), Lymphoma |
Details
|
LCAR-B4822M |
LCAR-B4822M,LCAR B4822M,LCARB4822M |
Phase Ⅰ |
GenScript Biotech Corporation |
Multiple myeloma (MM) |
Details
|
CAR-BCMA T cell therapy |
CT-053-CARsgen,CT053 |
Phase Ⅱ |
CARsgen Therapeutics |
Multiple myeloma (MM) |
Details
|
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) |
BCMA-CART |
Phase Ⅰ |
Shanghai Hrain Biotechnology |
Multiple myeloma (MM) |
Details
|
JNJ-64007957 |
JNJ-7957; JNJ-64007957; JNJ-64007959 |
Phase Ⅰ |
Janssen, Genmab |
Multiple myeloma (MM) |
Details
|
BCMA CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase Ⅱ |
Chongqing Precision Biotech |
Plasma cell neoplasms, Multiple myeloma (MM) |
Details
|
AUTO-2 |
AUTO-2; SUB-96123,AUTO 2; SUB 96123 |
Phase Ⅱ |
Autolus |
Multiple myeloma (MM) |
Details
|
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) |
|
Phase Ⅱ |
Chongqing Precision Biotech |
Multiple myeloma (MM) |
Details
|
CC-93269 |
CC-93269; EM-901 |
Phase Ⅰ |
Celgene |
Multiple myeloma (MM) |
Details
|
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase Ⅲ |
The First Affiliated Hospital of Soochow University |
Multiple myeloma (MM) |
Details
|
ACTR 087/SEA BCMA combination therapy |
|
Phase Ⅰ |
Unum Therapeutics, Seattle Genetics |
Multiple myeloma (MM) |
Details
|
anti-BCMA CAR T-cell Therapy (Juno Therapeutics) |
ET-140; ET140-CAR; JCARH-125; FCARH-143; MCARH-171 |
Phase Ⅱ |
Juno Therapeutics |
Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas |
Details
|
ALLO-715 |
ALLO-715 |
Phase Ⅰ |
Allogene Therapeutics, Cellectis |
Multiple myeloma (MM) |
Details
|
BCBM CAR T cell (Pregene) |
|
Phase Not Specified |
Pregene, BioCast |
Multiple myeloma (MM) |
Details
|